Articles & guides
Patient-facing explainers on cross-border specialty drug access, regulatory frameworks, and the Named Patient Program landscape.
Understanding Named Patient Programs
An introduction to how Named Patient Programs enable access to specialty drugs.
How Cross-Border Prescriptions Work
A walkthrough of the physician and regulatory steps.
What is DSCSA and Why It Matters
The Drug Supply Chain Security Act explained for international patients.
Rare Disease Access — A Global View
How different countries handle rare-disease drug access.
Questions to Ask Before Ordering Specialty Drugs Internationally
Key questions patients should ask.
The Difference Between NPP and Clinical Trials
How named-patient access differs from participating in a trial.
How Patients in the UAE Access Unregistered Drugs
A patient-centric guide to UAE's MOHAP and DoH pathways.
A Guide to Access Pathways in Saudi Arabia
SFDA Personal Import for patients and physicians.
Rule 36 Explained — India's Personal Import Pathway
How India's CDSCO personal-import rules work.
The Role of the Treating Physician in Cross-Border Access
Physician obligations and best practices.
Why Prepayment Is the Standard for NPP
Economic and regulatory reasons behind patient prepay.
Specialty Drug Storage and Cold Chain Basics
How temperature-controlled specialty drugs are handled.
How to Prepare for a First Shipment
A checklist for patients receiving international specialty drugs.
Understanding Orphan Drug Designation
What orphan designation means for access.
Gene Therapy Access — What to Know
Special considerations for gene-therapy access.
Insurance and Reimbursement for International Drugs
The reimbursement landscape for NPP drugs.
Counterfeit Drug Risk — How to Protect Yourself
How to verify legitimate supply chains.
Serialization and Chain of Custody
How DSCSA serialization protects patients.
The FDA, EMA, and International Approvals — A Primer
How different regulators relate to named-patient access.
Patient Stories — Rare Disease Access Journeys
Anonymized stories of cross-border access.
Working with Your Hospital Ethics Committee
How to navigate IEC/IRB approval for NPP.
Pediatric Rare Disease — Access Considerations
Special pediatric access considerations.
Oncology NPP — A Patient Primer
Cross-border access for oncology patients.
Immunology and Rheumatology NPP Access
Cross-border access in immunology.
Hematology NPP — Sickle Cell, Hemophilia, and More
Access for hematology patients.
Neurology NPP — ALS, MS, SMA, and More
Access for neurology patients.
What Physicians Need to Know About NPP Documentation
Physician documentation best practices.
The Ethics of Cross-Border Specialty Drug Access
Ethical considerations for patients and providers.
Pharmacovigilance and Adverse Event Reporting for NPP
AE reporting responsibilities in NPP.
Global Rare Disease Day — Why Access Matters
The broader access conversation.
How Manufacturers Design NPP Programs
A look inside manufacturer NPP strategies.
The Future of Cross-Border Drug Access
Emerging trends in global drug access.
Patient Assistance Programs — A Primer
Manufacturer and foundation-based patient assistance.
Travelling with Specialty Drugs — Practical Tips
Tips for patients carrying specialty drugs.
A Glossary of NPP and Access Terms
Definitions of common cross-border access terms.
Cross-Border Oncology — A Patient's Guide
Oncology-specific guide.
The Importance of Physician Oversight in NPP
Why physician oversight is essential.
When a Drug Is Not Registered — Your Options
What patients should consider.
Q&A — Common Patient Questions About NPP
Patient FAQs about NPP.
How to Read an NPP Approval Letter
Understanding approval-letter language.